Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post–allogeneic hematopoietic stem cell transplant patient-Reference-Cited by-同舟云学术

Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post–allogeneic hematopoietic stem cell transplant patient

Published:2020-06-02 Issue:11 Volume:4 Page:2387-2391
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Oza Aabha¹,Rettig Michael P.¹,Powell Phil¹,O’Brien Kathryn¹,Clifford David B.²^ORCID,Ritchey Julie¹,Gehrs Leah¹,Hollaway Julia¹,Major Eugene³,Fehniger Todd A.¹^ORCID,Miller Christopher A.⁴,Soon-Shiong Patrick⁵,Rock Amy⁵,DiPersio John F.¹^ORCID

Affiliation:

1. Division of Oncology and

2. Department of Neurology, Washington University in St. Louis, St. Louis, MO;

3. Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD;

4. McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO; and

5. ImmunityBio, Inc., Culver City, CA

Abstract

Key Points Therapy with an IL-15 superagonist resulted in immune and clinical responses in a transplant recipient with PML.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/4/11/2387/1743383/advancesadv2019000664.pdf

Reference37 articles.

1. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS);Bauer;Acta Neuropathol,2015